Alain Kentos - Academia.edu (original) (raw)
Papers by Alain Kentos
P atients with advanced Hodgkin disease (HD) who have a relapse after first-line chemotherapy can... more P atients with advanced Hodgkin disease (HD) who have a relapse after first-line chemotherapy can achieve further remissions with high-dose chemotherapy and transplantation of hematopoietic stem cells. Unfortunately, relapse or disease progression after autologous transplant occurs in a significant proportion of cases, and no clear treatment guidelines exist for these patients. We report the case of a patient with a refractory localized HD who had a sustained long-term remission (39 months) after surgery alone.
Syndrome de coagulation intravasculaire disséminée révélateur de la généralisation d'un adénocarcinome mammaire
Revue Médicale de Bruxelles, 1997
La survenue d'une coagulation intravasculaire disseminee au cours de l'evolution d'un... more La survenue d'une coagulation intravasculaire disseminee au cours de l'evolution d'une pathologie maligne est un phenomene connu, en particulier en ce qui concerne les cancers mucosecretants. Il apparait beaucoup plus rare, en revanche, de rencontrer ce syndrome de facon tres precoce avant l'apparition de signes cliniques evidents de neoplasie. Nous rapportons le cas d'une CIVD subaigue, se presentant a deux reprises comme symptome inaugural de la generalisation d'un cancer mammaire.
Clinical Transplantation, 2006
Abstract: Background: Post‐transplant lymphoproliferative disorders (PTLD) are potentially lethal... more Abstract: Background: Post‐transplant lymphoproliferative disorders (PTLD) are potentially lethal complications of solid organ transplantation. We, here, report on our experience with rituximab, an anti‐CD20 monoclonal antibody, as first‐line treatment for PTLD in six lung transplant recipients.
Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study
Blood
Introduction Data from clinical trials indicate that elderly non-transplant eligible newly diagno... more Introduction Data from clinical trials indicate that elderly non-transplant eligible newly diagnosed multiple myeloma (nte-NDMM) patients also benefit from novel therapies. However, overall survival is inferior in unfit and frail compared to fit patients as defined by the International Myeloma Working Group (IMWG) frailty index, caused by a high discontinuation rate due to toxicity. Therefore, there is a need for less toxic treatment for unfit and frail patients. In view of the favorable safety profile of ixazomib and daratumumab, we investigated the efficacy and feasibility of treatment with ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail patients. This trial was registered at www.trialregister.nl as NTR6297. Methods In this prospective multicenter phase II trial treatment consisted of 9 28 day-induction cycles consisting of ixazomib (I) 4 mg (days 1, 8, 15), daratumumab (D) 16 mg/kg (cycle 1-2: days 1, 8, 15, 22; cycle 3-6: days 1, 15; cycle 7-9: day 1) a...
Acta Clinica Belgica
With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal ... more With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice.
Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study
Blood
BACKGROUND The combination of pomalidomide (POM) and dexamethasone (DEX) for the treatment (Tx) o... more BACKGROUND The combination of pomalidomide (POM) and dexamethasone (DEX) for the treatment (Tx) of relapsed or refractory multiple myeloma (RRMM) in patients (pts) who have received ≥ 2 prior Tx regimens, including lenalidomide (LEN) and bortezomib (BORT), was approved in Europe in August 2013. POM-DEX is now a standard Tx for pts with RRMM. These pts are at an increased risk for adverse events (AEs) due to prior exposure to multiple lines of Tx and a high disease burden. The European Union post-authorization safety study (EU PASS; NCT02164955) is a prospective, observational, non-interventional study (method: registry) designed to characterize the safety profile of POM-based Tx in pts with RRMM in a real-world setting. AIM To report the incidence of key AEs with POM-based Tx, such as neutropenia, thrombocytopenia, venous thromboembolism (VTE), peripheral neuropathy (PN), and second primary malignancies (SPMs), in pts with RRMM treated with POM according to the last prior Tx before ...
Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry
Blood
Background Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult pa... more Background Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult patients with resistant or intolerant chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), or those with the T315I mutation. In Belgium, ponatinib has been commercially available since March 2016. The goal of this registry was to collect efficacy and safety data in CML and Ph+ ALL patients and to evaluate ponatinib in routine clinical practice in Belgium. Methods This ongoing, prospective, multi-center registry includes patients ≥18 years of age with CML or Ph+ ALL, who have initiated ponatinib treatment. Demographic, efficacy and safety data were collected for patients enrolled from March 2016 (day 0) onwards. Results up to study month 24 are presented. Data were analyzed by descriptive statistics. Ethics Committee approval was obtained and all patients provided informed consent. R...
Valproic Acid Induces Apoptosis in Chronic Lymphocytic Leukemia Cells by Targeting Several Pro- and Anti-Apoptotic Genes
Blood
Histone deacetylase inhibitors have been shown to modulate the cell cycle, to induce apoptosis an... more Histone deacetylase inhibitors have been shown to modulate the cell cycle, to induce apoptosis and to sensitize cancer cells to other chemotherapeutics. Among these inhibitors, valproic acid (VPA), an antiepileptic drug, is being discussed as a promising novel anti-cancer drug. Chronic Lymphocytic Leukemia (CLL) is a clinically heterogeneous disease remaining incurable despite introducing new promising treatments. The effects of VPA and its mechanism of action were evaluated on mononuclear cells isolated from 40 CLL patients. Exposure of CLL cells to increased doses of VPA (0.5–5mM) leads to a dose-dependent cytotoxicity and apoptosis in all CLL patients. VPA treatment induced apoptotic changes in CLL cells including phosphatidylserine externalization and DNA fragmentation. The mean apoptotic rates were similar between IGHV mutated and unmutated patients, the latter presenting a more aggressive clinical course. VPA induced apoptosis via the extrinsic pathway involving engagement of ...
The Lancet
Background Maintenance therapy following autologous stem cell transplantation can delay disease p... more Background Maintenance therapy following autologous stem cell transplantation can delay disease progression and prolong survival in multiple myeloma (MM). Ixazomib is ideally suited for maintenance therapy given its efficacy, convenient once-weekly oral dosing, and low toxicity profile. Methods The phase 3, double-blind, placebo-controlled, TOURMALINE-MM3 study randomised 656 patients with newly diagnosed MM from 227 clinical/hospital sites in 30 countries in Europe, the Middle East, Africa,
Reply to M. Lambertini et al
Journal of Clinical Oncology, 2017
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (... more We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up. A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy. Ovarian function and fertility were reported after 2, 3, 4, and 5 to 7 years of follow up. The primary end point was POF, defined as at least one follicle-stimulating hormone value of > 40 IU/L after 2 years of follow up. Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452). Multivariate logistic regression analysis showed a significantly increased risk o...
Eur J Nucl Med Mol Imaging, 2001
Bacillus cereus pneumonia in a patient with acute lymphoblastic leukemia
European Journal of Clinical Microbiology Infectious Diseases Official Publication of the European Society of Clinical Microbiology, Aug 6, 2004
Reported here is a case of Bacillus cereus pneumonia that occurred in a patient with acute lympho... more Reported here is a case of Bacillus cereus pneumonia that occurred in a patient with acute lymphoblastic leukemia. The presentation was severe, essentially marked by respiratory distress and pleuritic chest pain. Classic empirical treatment initiated for febrile neutropenia did not cover this rare pathogen and appropriate therapy was therefore delayed. B. cereus is most often a culture contaminant, but it can also be responsible for self-limited gastrointestinal intoxication and, more rarely, severe systemic diseases. Virulence in the case of systemic disease is attributed to tissue necrosis mediated by toxin release. B. cereus pneumonia, as described in the English-language literature, mainly affects immunocompromised patients and most often has a fatal outcome. Thus, the identification of B. cereus in clinical specimens of severely ill immunocompromised patients should lead physicians to question its clinical significance.
Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission
Clinical Transplantation, 2006
All-trans retinoic acid induced thrombocytosis in a patient with acute promyelocytic leukaemia
British Journal of Haematology
Subcutaneous panniculitis-like T-cell lymphoma: further evidence for a distinct neoplasm originating from large granular lymphocytes of T/NK phenotype
Journal of Cutaneous Pathology
We report the case of a 20 year-old caucasian woman who presented a primary subcutaneous pannicul... more We report the case of a 20 year-old caucasian woman who presented a primary subcutaneous panniculitis-like T-cell lymphoma (SPTCL) as an invasive tumor of the chest wall. Herein, the neoplastic cells were found to express a CD3+CD8+ phenotype but also displayed variably the natural killer (NK)-associated antigens CD56 and CD57 as well as granzyme B. On cytological examination, these cells showed a large granular lymphocyte (LGL)-like morphology with presence of azurophilic granules in their cytoplasm. Electron dense and membrane bound granules like those found in cytotoxic T lymphocytes (CTL) were also demonstrated by electron microscopy. Neither rearrangement of the T-cell receptor subunits nor Epstein-Barr virus (EBV) genome was observed at the molecular level. The LGL-like features of the neoplastic cells found in this case and the presence of NK-associated antigens provide additional support to the cytotoxic derivation of most SPTCL.
L’espace enfants/adolescents, un lieu d’accueil pour les enfants et les adolescents dont un parent est atteint d’un cancer
Psycho-Oncologie, 2012
ABSTRACT L’espace enfants/adolescents est un lieu d’accueil à l’hôpital, mis en place en collabor... more ABSTRACT L’espace enfants/adolescents est un lieu d’accueil à l’hôpital, mis en place en collaboration avec les équipes soignant les patients adultes atteints d’un cancer, pour leurs enfants, adolescents, familles et proches venant leur rendre visite. Ce lieu adapté aux enfants maintient le lien familial. Deux psychologues l’animent et favorisent l’expression des émotions via des médias projectifs : dessin, matériel de bricolage, trousse de docteur, « Playmobil », jeux de société… L’accès est libre tous les mercredis après-midi.
[Cardiac arrhythmias and superior vena cava syndrome revealing a Richter's syndrome]
Revue médicale de Bruxelles
Richter's syndrome is the aggressive transformation of chronic lymphocytic leukemia in a diff... more Richter's syndrome is the aggressive transformation of chronic lymphocytic leukemia in a diffuse large cell lymphoma. The locations and the clinical manifestations are varied. We report the case of a Richter's syndrome revealed by cardiac arrhythmias and superior vena cava syndrome in a patient of 78 years followed during 2 years for chronic lymphocytic leukemia.
[Non Hodgkin's lymphomas: a major breakthrough with immunotherapy]
Revue médicale de Bruxelles
Non hodgkin's lymphomas are a group of haematological malignancies in which spectacular progr... more Non hodgkin's lymphomas are a group of haematological malignancies in which spectacular progress has been made over the last ten years thanks to immunotherapy. Furthermore, the new WHO classification, based upon tumour immunology, the degree of tumour differentiation and cytogenetic abnormalities, has finally improved identification of each lymphoma and has enabled comparison of homogeneous populations between different clinical studies. The increase in the incidence of non hodgkin's lymphoma is related to the aging of the population and to other factors that are yet to be elucidated--a real challenge for the future. We have tried to offer an overview of the latest therapeutic advances, with a focus on (radio-) immunotherapy and haemopoietic stem cell transplantation.
P atients with advanced Hodgkin disease (HD) who have a relapse after first-line chemotherapy can... more P atients with advanced Hodgkin disease (HD) who have a relapse after first-line chemotherapy can achieve further remissions with high-dose chemotherapy and transplantation of hematopoietic stem cells. Unfortunately, relapse or disease progression after autologous transplant occurs in a significant proportion of cases, and no clear treatment guidelines exist for these patients. We report the case of a patient with a refractory localized HD who had a sustained long-term remission (39 months) after surgery alone.
Syndrome de coagulation intravasculaire disséminée révélateur de la généralisation d'un adénocarcinome mammaire
Revue Médicale de Bruxelles, 1997
La survenue d'une coagulation intravasculaire disseminee au cours de l'evolution d'un... more La survenue d'une coagulation intravasculaire disseminee au cours de l'evolution d'une pathologie maligne est un phenomene connu, en particulier en ce qui concerne les cancers mucosecretants. Il apparait beaucoup plus rare, en revanche, de rencontrer ce syndrome de facon tres precoce avant l'apparition de signes cliniques evidents de neoplasie. Nous rapportons le cas d'une CIVD subaigue, se presentant a deux reprises comme symptome inaugural de la generalisation d'un cancer mammaire.
Clinical Transplantation, 2006
Abstract: Background: Post‐transplant lymphoproliferative disorders (PTLD) are potentially lethal... more Abstract: Background: Post‐transplant lymphoproliferative disorders (PTLD) are potentially lethal complications of solid organ transplantation. We, here, report on our experience with rituximab, an anti‐CD20 monoclonal antibody, as first‐line treatment for PTLD in six lung transplant recipients.
Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study
Blood
Introduction Data from clinical trials indicate that elderly non-transplant eligible newly diagno... more Introduction Data from clinical trials indicate that elderly non-transplant eligible newly diagnosed multiple myeloma (nte-NDMM) patients also benefit from novel therapies. However, overall survival is inferior in unfit and frail compared to fit patients as defined by the International Myeloma Working Group (IMWG) frailty index, caused by a high discontinuation rate due to toxicity. Therefore, there is a need for less toxic treatment for unfit and frail patients. In view of the favorable safety profile of ixazomib and daratumumab, we investigated the efficacy and feasibility of treatment with ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail patients. This trial was registered at www.trialregister.nl as NTR6297. Methods In this prospective multicenter phase II trial treatment consisted of 9 28 day-induction cycles consisting of ixazomib (I) 4 mg (days 1, 8, 15), daratumumab (D) 16 mg/kg (cycle 1-2: days 1, 8, 15, 22; cycle 3-6: days 1, 15; cycle 7-9: day 1) a...
Acta Clinica Belgica
With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal ... more With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice.
Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study
Blood
BACKGROUND The combination of pomalidomide (POM) and dexamethasone (DEX) for the treatment (Tx) o... more BACKGROUND The combination of pomalidomide (POM) and dexamethasone (DEX) for the treatment (Tx) of relapsed or refractory multiple myeloma (RRMM) in patients (pts) who have received ≥ 2 prior Tx regimens, including lenalidomide (LEN) and bortezomib (BORT), was approved in Europe in August 2013. POM-DEX is now a standard Tx for pts with RRMM. These pts are at an increased risk for adverse events (AEs) due to prior exposure to multiple lines of Tx and a high disease burden. The European Union post-authorization safety study (EU PASS; NCT02164955) is a prospective, observational, non-interventional study (method: registry) designed to characterize the safety profile of POM-based Tx in pts with RRMM in a real-world setting. AIM To report the incidence of key AEs with POM-based Tx, such as neutropenia, thrombocytopenia, venous thromboembolism (VTE), peripheral neuropathy (PN), and second primary malignancies (SPMs), in pts with RRMM treated with POM according to the last prior Tx before ...
Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry
Blood
Background Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult pa... more Background Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult patients with resistant or intolerant chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), or those with the T315I mutation. In Belgium, ponatinib has been commercially available since March 2016. The goal of this registry was to collect efficacy and safety data in CML and Ph+ ALL patients and to evaluate ponatinib in routine clinical practice in Belgium. Methods This ongoing, prospective, multi-center registry includes patients ≥18 years of age with CML or Ph+ ALL, who have initiated ponatinib treatment. Demographic, efficacy and safety data were collected for patients enrolled from March 2016 (day 0) onwards. Results up to study month 24 are presented. Data were analyzed by descriptive statistics. Ethics Committee approval was obtained and all patients provided informed consent. R...
Valproic Acid Induces Apoptosis in Chronic Lymphocytic Leukemia Cells by Targeting Several Pro- and Anti-Apoptotic Genes
Blood
Histone deacetylase inhibitors have been shown to modulate the cell cycle, to induce apoptosis an... more Histone deacetylase inhibitors have been shown to modulate the cell cycle, to induce apoptosis and to sensitize cancer cells to other chemotherapeutics. Among these inhibitors, valproic acid (VPA), an antiepileptic drug, is being discussed as a promising novel anti-cancer drug. Chronic Lymphocytic Leukemia (CLL) is a clinically heterogeneous disease remaining incurable despite introducing new promising treatments. The effects of VPA and its mechanism of action were evaluated on mononuclear cells isolated from 40 CLL patients. Exposure of CLL cells to increased doses of VPA (0.5–5mM) leads to a dose-dependent cytotoxicity and apoptosis in all CLL patients. VPA treatment induced apoptotic changes in CLL cells including phosphatidylserine externalization and DNA fragmentation. The mean apoptotic rates were similar between IGHV mutated and unmutated patients, the latter presenting a more aggressive clinical course. VPA induced apoptosis via the extrinsic pathway involving engagement of ...
The Lancet
Background Maintenance therapy following autologous stem cell transplantation can delay disease p... more Background Maintenance therapy following autologous stem cell transplantation can delay disease progression and prolong survival in multiple myeloma (MM). Ixazomib is ideally suited for maintenance therapy given its efficacy, convenient once-weekly oral dosing, and low toxicity profile. Methods The phase 3, double-blind, placebo-controlled, TOURMALINE-MM3 study randomised 656 patients with newly diagnosed MM from 227 clinical/hospital sites in 30 countries in Europe, the Middle East, Africa,
Reply to M. Lambertini et al
Journal of Clinical Oncology, 2017
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (... more We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up. A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy. Ovarian function and fertility were reported after 2, 3, 4, and 5 to 7 years of follow up. The primary end point was POF, defined as at least one follicle-stimulating hormone value of > 40 IU/L after 2 years of follow up. Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452). Multivariate logistic regression analysis showed a significantly increased risk o...
Eur J Nucl Med Mol Imaging, 2001
Bacillus cereus pneumonia in a patient with acute lymphoblastic leukemia
European Journal of Clinical Microbiology Infectious Diseases Official Publication of the European Society of Clinical Microbiology, Aug 6, 2004
Reported here is a case of Bacillus cereus pneumonia that occurred in a patient with acute lympho... more Reported here is a case of Bacillus cereus pneumonia that occurred in a patient with acute lymphoblastic leukemia. The presentation was severe, essentially marked by respiratory distress and pleuritic chest pain. Classic empirical treatment initiated for febrile neutropenia did not cover this rare pathogen and appropriate therapy was therefore delayed. B. cereus is most often a culture contaminant, but it can also be responsible for self-limited gastrointestinal intoxication and, more rarely, severe systemic diseases. Virulence in the case of systemic disease is attributed to tissue necrosis mediated by toxin release. B. cereus pneumonia, as described in the English-language literature, mainly affects immunocompromised patients and most often has a fatal outcome. Thus, the identification of B. cereus in clinical specimens of severely ill immunocompromised patients should lead physicians to question its clinical significance.
Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission
Clinical Transplantation, 2006
All-trans retinoic acid induced thrombocytosis in a patient with acute promyelocytic leukaemia
British Journal of Haematology
Subcutaneous panniculitis-like T-cell lymphoma: further evidence for a distinct neoplasm originating from large granular lymphocytes of T/NK phenotype
Journal of Cutaneous Pathology
We report the case of a 20 year-old caucasian woman who presented a primary subcutaneous pannicul... more We report the case of a 20 year-old caucasian woman who presented a primary subcutaneous panniculitis-like T-cell lymphoma (SPTCL) as an invasive tumor of the chest wall. Herein, the neoplastic cells were found to express a CD3+CD8+ phenotype but also displayed variably the natural killer (NK)-associated antigens CD56 and CD57 as well as granzyme B. On cytological examination, these cells showed a large granular lymphocyte (LGL)-like morphology with presence of azurophilic granules in their cytoplasm. Electron dense and membrane bound granules like those found in cytotoxic T lymphocytes (CTL) were also demonstrated by electron microscopy. Neither rearrangement of the T-cell receptor subunits nor Epstein-Barr virus (EBV) genome was observed at the molecular level. The LGL-like features of the neoplastic cells found in this case and the presence of NK-associated antigens provide additional support to the cytotoxic derivation of most SPTCL.
L’espace enfants/adolescents, un lieu d’accueil pour les enfants et les adolescents dont un parent est atteint d’un cancer
Psycho-Oncologie, 2012
ABSTRACT L’espace enfants/adolescents est un lieu d’accueil à l’hôpital, mis en place en collabor... more ABSTRACT L’espace enfants/adolescents est un lieu d’accueil à l’hôpital, mis en place en collaboration avec les équipes soignant les patients adultes atteints d’un cancer, pour leurs enfants, adolescents, familles et proches venant leur rendre visite. Ce lieu adapté aux enfants maintient le lien familial. Deux psychologues l’animent et favorisent l’expression des émotions via des médias projectifs : dessin, matériel de bricolage, trousse de docteur, « Playmobil », jeux de société… L’accès est libre tous les mercredis après-midi.
[Cardiac arrhythmias and superior vena cava syndrome revealing a Richter's syndrome]
Revue médicale de Bruxelles
Richter's syndrome is the aggressive transformation of chronic lymphocytic leukemia in a diff... more Richter's syndrome is the aggressive transformation of chronic lymphocytic leukemia in a diffuse large cell lymphoma. The locations and the clinical manifestations are varied. We report the case of a Richter's syndrome revealed by cardiac arrhythmias and superior vena cava syndrome in a patient of 78 years followed during 2 years for chronic lymphocytic leukemia.
[Non Hodgkin's lymphomas: a major breakthrough with immunotherapy]
Revue médicale de Bruxelles
Non hodgkin's lymphomas are a group of haematological malignancies in which spectacular progr... more Non hodgkin's lymphomas are a group of haematological malignancies in which spectacular progress has been made over the last ten years thanks to immunotherapy. Furthermore, the new WHO classification, based upon tumour immunology, the degree of tumour differentiation and cytogenetic abnormalities, has finally improved identification of each lymphoma and has enabled comparison of homogeneous populations between different clinical studies. The increase in the incidence of non hodgkin's lymphoma is related to the aging of the population and to other factors that are yet to be elucidated--a real challenge for the future. We have tried to offer an overview of the latest therapeutic advances, with a focus on (radio-) immunotherapy and haemopoietic stem cell transplantation.